Completed PHASE3 INTERVENTIONAL 3-arm NCT03158285

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis

Sponsor: Janssen Research & Development, LLC

Conditions Arthritis, Psoriatic

Interventions Guselkumab Placebo

Updated 40 times since 2017 Last updated: Dec 20, 2022 Started: Jul 12, 2017 Primary completion: Feb 25, 2019 Completion: Nov 10, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03158285, this PHASE3 trial focuses on Arthritis, Psoriatic and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 40 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

40 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Dec 2025 — Feb 2026 [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 35 earlier versions

Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2022 — Jan 2023 [monthly]

Completed PHASE3
Feb 2021 — Jan 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Sep 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE3
Jun 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE3
May 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Active Not Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Active Not Recruiting PHASE3
Sep 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2019 — Jul 2019 [monthly]

Active Not Recruiting PHASE3
May 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE3
Apr 2019 — May 2019 [monthly]

Active Not Recruiting PHASE3
Mar 2019 — Apr 2019 [monthly]

Active Not Recruiting PHASE3
Feb 2019 — Mar 2019 [monthly]

Active Not Recruiting PHASE3
Jan 2019 — Feb 2019 [monthly]

Active Not Recruiting PHASE3
Dec 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3
Nov 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Mar 2018 — May 2018 [monthly]

Recruiting PHASE3
Jan 2018 — Mar 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2017 — Aug 2017 [monthly]

Not Yet Recruiting PHASE3
Jun 2017 — Jul 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Antalya, Turkey (Türkiye) , Austin, United States , Barakaldo, Spain , Batu Caves, Malaysia , Bilbao, Spain , Birmingham, United States , Brno, Czechia and 95 more locations